(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 May 2012 (31.05.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/069948 A1

(51) International Patent Classification:
C07D 401/04 (2006.01) *A61K 31/454* (2006.01)
C07D 401/14 (2006.01) *A61K 31/506* (2006.01)
C07D 403/14 (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:
PCT/IB2011/054996

(22) International Filing Date:
9 November 2011 (09.11.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/416,441 23 November 2010 (23.11.2010) US

(71) Applicant *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MASCITTI, Vincent** [FR/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **MCCLURE, Kim Francis** [US/US]; Pfizer Global Research and Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US). **MUNCHHOF, Michael John** [US/US]; 266 West Road, Salem, Connecticut 06420 (US). **ROBINSON, Ralph Pelton, Jr.** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US).

(74) Agent: **KLEIMAN, Gabriel, L.**; Pfizer Inc. 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

WO 2012/069948 A1

(54) Title: 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS

(57) Abstract: Compounds that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein- coupled receptor GPR119 in animals are described herein.